Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Artificial intelligence is entering the era of self-improvement. On Thursday afternoon, OpenAI released a new cutting-edge coding model that the company said assisted in its own creation.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Ludi Akue discusses how the tech sector’s ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

Nature is its own most incorrigible plagiarist; echoes of the same aesthetic motifs show up in all kinds of places and all kinds of scales. Here, the finned texture resembles the underside of a ...

According to DeepLearning.AI, Samsung’s Tiny Recursive Model (TRM) utilizes iterative answer refinement and maintains a context of previous changes to tackle complex grid puzzles such as Sudoku, Mazes ...

Abstract: Heterogeneous device-edge-cloud computing infrastructures have become the backbone of modern telecommunication operators and Wide Area Networks (WANs), providing multi-tier computational ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.